CHHT-Alvotech JV Signs China Deal to Commercialize Biosimilars
November 24, 2020 at 05:43 AM EST
The China biosimilar JV formed by Changchun High & New Technology and Iceland 's Alvotech has signed up Yangtze River Pharma to commercialize their eight biosimilar candidates in China . The JV, CAHT, will manufacture the products. CAHT is developing biosimilar candidates for autoimmunity, ophthalmology, and oncology diseases, plus immune and inflammatory conditions. Established in 2019, CAHT was funded with $110 million in capital at a $200 million valuation. More details.... Share this with colleagues: // //
